1. Home
  2. ASPI vs GERN Comparison

ASPI vs GERN Comparison

Compare ASPI & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ASP Isotopes Inc.

ASPI

ASP Isotopes Inc.

HOLD

Current Price

$5.05

Market Cap

783.1M

Sector

Industrials

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.48

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASPI
GERN
Founded
2021
1990
Country
United States
United States
Employees
N/A
258
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
783.1M
808.3M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
ASPI
GERN
Price
$5.05
$1.48
Analyst Decision
Strong Buy
Hold
Analyst Count
2
3
Target Price
$12.00
$2.17
AVG Volume (30 Days)
4.7M
15.0M
Earning Date
04-10-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$23,849,000.00
N/A
Revenue This Year
$68.41
$26.91
Revenue Next Year
$126.69
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
475.48
N/A
52 Week Low
$3.92
$1.04
52 Week High
$14.49
$2.01

Technical Indicators

Market Signals
Indicator
ASPI
GERN
Relative Strength Index (RSI) 34.91 68.28
Support Level $3.98 $1.44
Resistance Level $6.02 $1.72
Average True Range (ATR) 0.62 0.09
MACD -0.21 0.03
Stochastic Oscillator 2.21 95.83

Price Performance

Historical Comparison
ASPI
GERN

About ASPI ASP Isotopes Inc.

ASP Isotopes Inc is a materials company focused on producing and commercializing enriched isotopes for the nuclear medicine, healthcare, green energy, and quantum computing industries. Currently, the company has three operating segments: (i) nuclear fuels, (ii) specialist isotopes and related services, and (iii) construction services. Using proprietary technology-the Aerodynamic Separation Process (ASP)-the company enriches isotopes in South Africa, targeting high-value, low-volume markets to reduce reliance on foreign supply chains. Geographically, the company operates in South Africa, Hong Kong and United States generating key revenue from the Hong Kong region.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: